Crossmark

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

Crossref DOI link: https://doi.org/10.1016/j.reumae.2017.04.009

Published Print: 2019-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Burgos-Vargas, Ruben

Cardiel, Mario

Xibillèc), Daniel

Pacheco-Tena, Cèc)sar

Pascual-Ramos, Virginia

Abud-Mendoza, Carlos

Mahgoub, Ehab

Rahman, Mahboob

Fan, Haiyun

Rojo, Ricardo

García, Erika

Santana, Karina
License Information

Text and Data Mining valid from 2019-01-01
More Information

This article is maintained by: Elsevier

Article Title: Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2017.04.009

Content Type: article

Copyright: © 2017 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Document is current

Any future updates will be listed below